ARCUATE THERAPEUTICS
Arcuate Therapeutics is a provider of stealth healthcare service.
ARCUATE THERAPEUTICS
Industry:
Health Care
Founded:
2019-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
5 M USD
Similar Organizations
858 Therapeutics
858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology.
Centric Health Corp.
Centric Health Corp. operates as a provider of healthcare services.
Respiree
Respiree is a healthcare service.
Current Employees Featured
Founder
More informations about "Arcuate Therapeutics"
ARCUATE THERAPEUTICS, INC. :: Massachusetts (US)
Oct 3, 2019 Free and open company data on Massachusetts (US) company ARCUATE THERAPEUTICS, INC. (company number 001405172), 200 BERKELEY ST., C/O RA …See details»
Arcuate Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Arcuate Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Arcuate Therapeutics - Products, Competitors, Financials, …
Arcuate Therapeutics was founded in 2019. Where is Arcuate Therapeutics's headquarters? Arcuate Therapeutics's headquarters is located at 200 Berkeley Street, Boston.See details»
Arcuate Therapeutics - Contacts, Employees, Board Members
Arcuate Therapeutics is a provider of stealth healthcare service. Start Free Trial . Chrome ExtensionSee details»
ACTUATE THERAPEUTICS RECEIVES FDA ORPHAN DRUG …
Actuate is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for high impact cancers and inflammatory diseases. …See details»
The renin-angiotensin system in the arcuate nucleus controls …
Despite decades of efforts to halt disease progression, the World Health Organization has published that approximately 39% of the world’s ... it is unsurprising that most anti-obesity …See details»
ACTUATE THERAPEUTICS COMPLETES $21.7 MILLION SERIES B …
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised $21.7 Million in a Series B …See details»
Arcuate Therapeutics - Funding, Financials, Valuation & Investors
Arcuate Therapeutics is a provider of stealth healthcare service. How much funding has this organization raised over time? ShowSee details»
Actuate Therapeutics Company Profile 2024: Stock
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing …See details»
Targeting Hard-to-Treat Cancers | Actuate Therapeutics
Actuate aims to give patients with hard-to-treat cancers the opportunity to live longer and better with the potential capacity to slow, stop, or shrink tumors, with minimal adverse effects.. Actuate’s lead drug, elraglusib (a novel GSK-3 …See details»
Arcuate Therapeutics - Crunchbase
Organization. Arcuate Therapeutics . Connect to CRM . Save . Summary Financials People Signals & News Similar Companies. Similar Companies. Edit Similar Companies Section. …See details»
Generation of hypothalamic arcuate organoids from human …
Current brain organoid models do not resolve fine subregions of the human brain. Ming et al. established a method to generate hypothalamic arcuate organoids from human induced …See details»
Actuate Therapeutics - Crunchbase Company Profile & Funding
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private biopharmaceutical company focused on the …See details»
Frontiers | Perspectives on (A)symmetry of Arcuate Fasciculus. A …
Feb 9, 2021 Figure 1.Preoperative (A–C) and postoperative (D–F) DTI tractography and fMRI study of an 18-year-old ambidextrous woman with a right frontotemporoinsular low-grade …See details»
Generation of hypothalamic arcuate organoids from human …
Sep 2, 2021 Generation of hypothalamic arcuate organoids from human induced pluripotent stem cells Author links open overlay panel Wei-Kai Huang 1 9 11 , Samuel Zheng Hao Wong …See details»
Media and Resources - Actuate Therapeutics
Sep 18, 2024 2024-AACR- FOLFIRINOX with glycogen synthase kinase-3 beta (GSK-3β) inhibitor elraglusib and transforming growth factor-β (TGFβ) inhibitor losartan in untreated …See details»
Investor Relations | Actuate Therapeutics
Nov 26, 2024 Actuate Therapeutics to be Added to Russell 2000® Index. November 12, 2024. Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for …See details»
Targeting GSK-3β to Treat Cancer | Actuate Therapeutics
GSK-3β is an enzyme that regulates a number of intersecting biological pathways that are associated with disease—most notably, cancer.GSK-3β drives tumor progression by …See details»
Improving Clinical Outcomes in Cancer Treatment - Actuate …
Our focus on glycogen synthase kinase-3β (the enzyme GSK-3β) has led to the development of the therapeutic candidate elraglusib (formerly known as 9-ING-41).Elraglusib has shown …See details»